Compare BYD & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BYD | CORT |
|---|---|---|
| Founded | 1973 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 9.7B |
| IPO Year | 1996 | 2001 |
| Metric | BYD | CORT |
|---|---|---|
| Price | $73.26 | $112.07 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 5 |
| Target Price | $90.82 | ★ $96.50 |
| AVG Volume (30 Days) | ★ 827.3K | 759.6K |
| Earning Date | 04-23-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.93% | N/A |
| EPS Growth | ★ 264.46 | N/A |
| EPS | ★ 3.12 | 0.09 |
| Revenue | ★ $2,626,730,000.00 | $761,407,000.00 |
| Revenue This Year | $1.71 | $26.08 |
| Revenue Next Year | $2.74 | $26.98 |
| P/E Ratio | ★ $23.80 | $1,276.22 |
| Revenue Growth | 9.41 | ★ 12.79 |
| 52 Week Low | $74.23 | $28.66 |
| 52 Week High | $91.41 | $126.38 |
| Indicator | BYD | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 26.41 | 47.72 |
| Support Level | N/A | $108.25 |
| Resistance Level | $90.37 | $124.30 |
| Average True Range (ATR) | 1.59 | 4.83 |
| MACD | -0.14 | -0.95 |
| Stochastic Oscillator | 1.95 | 28.50 |
Boyd Gaming Corp is a multi-jurisdictional gaming company. The company operates wholly-owned gaming entertainment properties (casino space, slot machines, table games, and hotel rooms) in Nevada, Illinois, Indiana, Iowa, Kansas, Louisiana, Mississippi, Missouri, Ohio, and Pennsylvania. Geographical regions separate its business segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Online. The Midwest and South hold the key number of entertainment properties and generate the majority of the company's revenue.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.